Effect of mebendazole on fibrosarcoma in hamsters

  • Dušica J Popović
  • Dušan Lalošević
  • Kosta J. Popović
  • Ivan Čapo
  • Jovan K. Popović
  • Dejan Miljković
Keywords: Mebendazole, Hamsters, BHK-21/C13 cells, Fibrosarcoma therapy, Tumor mitosis

Abstract

Purpose: To investigate the effect of mebendazole on an in vivo solid tumor model of fibrosarcoma in hamsters.
Methods: 24 Syrian golden hamsters of both sexes with the approximate body  weight of 100g were randomly distributed in 2 experimental and 2 control groups, with 6 animals in each group. BHK-21/C13 cells (2 x 106) in 1 mL Glasgow Minimum Essential Medium (GMEM) were injected subcutaneously into the back of each animal in 3 groups. The experimental groups were treated with mebendazole  (460 mg/kg) via a gastric tube on a daily basis, immediately after tumor inoculation. In addition, one experimental group received deoxycholic acid 20 mg/kg once a day. After 2 weeks, when the tumors were approximately 1 - 2 cm in the control group, all the animals were sacrificed, and their blood collected for laboratory analysis. The tumors were excised, their weight and diameters measured, and the volumes  calculated. The tumor samples were histopathologically assessed and the main organs toxicologically analyzed. Images were taken and processed by an imaging software, and Ki-67-positive cells in the tumor samples were quantified.
Results: Mebendazole diminished tumor mitosis from 18.5 ± 3.02 to 13.5 ± 3.45 (p < 0.05), vasculature and tissue penetration, and increased necroses in tumor  slices. Tumor volume and weight were insignificantly attenuated. Toxicity was not observed.
Conclusion: Mebendazole might be an effective non-toxic agent in sarcoma therapy.

Keywords: Mebendazole, Hamsters, BHK-21/C13 cells, Fibrosarcoma therapy,  Tumor mitosis

Published
2017-11-15
Section
Articles

Journal Identifiers


eISSN: 1596-9827
print ISSN: 1596-5996